Furthermore, immune checkpoint inhibitors, such as the anti-programmed cell death-1 (anti-PD-1) mAb nivolumab, are in phase II trial studies for the treatment of patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma [50]. The gene discussed is PDCD1; the disease is T-cell leukemia.